Form 4: Avadel Exec Sells Shares Post-Alkermes Acquisition

Avadel Pharmaceuticals General Counsel Jerad Seurer disposed of ordinary shares and stock options following the company's acquisition by Alkermes plc.

Summary

• Jerad G. Seurer, General Counsel & Corporate Secretary of Avadel Pharmaceuticals plc, reported the disposition of ordinary shares and stock options.
• The disposition occurred on February 12, 2026, in connection with the consummation of Avadel Pharmaceuticals plc's acquisition by Alkermes plc.
• Under the Transaction Agreement, each outstanding ordinary share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional $1.50 per share.
• 23,496 ordinary shares, including previously restricted stock awards that vested in full, were disposed of at a price of $21.00 per share.
• All outstanding stock options, whether vested or not, were canceled and exchanged for a cash amount (Cash Consideration minus exercise price) and one CVR for each underlying share.
• A total of 486,500 shares underlying stock options were disposed of across various tranches with exercise prices ranging from $4.69 to $13.57.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as positive for the reporting person, representing a successful liquidity event from their equity holdings. For the company, it marks the definitive and successful conclusion of a strategic acquisition, which is generally a positive outcome for the target company's shareholders.

Positives

• The reporting person realized significant cash value from the disposition of ordinary shares and stock options due to the acquisition.
• The acquisition by Alkermes plc provided a clear exit strategy and liquidity event for Avadel Pharmaceuticals plc shareholders, including executives.
• The transaction included a contingent value right (CVR) which offers a potential additional cash payment of $1.50 per share upon achievement of certain milestones, providing upside potential post-acquisition.

Negatives

• Avadel Pharmaceuticals plc ceased to be an independent publicly traded entity following its acquisition by Alkermes plc.
• The reporting person no longer holds direct equity in Avadel Pharmaceuticals plc, limiting future direct participation in the company's performance.

Risks

• The contingent value right (CVR) payment of $1.50 per share is not guaranteed and is contingent upon the achievement of unspecified milestones, introducing uncertainty regarding the full value realization.

Future Outlook

The independent future outlook for Avadel Pharmaceuticals plc is concluded due to its acquisition by Alkermes plc. The future financial outcome for former Avadel shareholders now largely depends on the performance of Alkermes plc and the achievement of milestones tied to the contingent value rights.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a standard regulatory disclosure following the completion of a corporate acquisition. Such filings are common as executives of the acquired company liquidate their equity holdings in accordance with the terms of the merger agreement. This event signifies the successful conclusion of a strategic transaction within the pharmaceutical industry, consolidating assets under Alkermes plc.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Avadel Pharmaceuticals plc received $21.00 in cash per ordinary share and one contingent value right (CVR) for a potential additional $1.50 per share.
• Employees holding equity (like the reporting person) had their shares and stock options converted into cash and CVRs, providing a liquidity event for their holdings.

Next Steps

• Potential future payment of $1.50 per share via contingent value rights, subject to the achievement of certain milestones.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Form 4, Insider Transaction, Stock Options, Contingent Value Right, Corporate Secretary, Scheme of Arrangement